A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women

Trial Profile

A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2017

At a glance

  • Drugs Alendronic acid/colecalciferol (Primary) ; Alendronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Apr 2010 Patient numbers amended from 350 to 343 as reported by ClinicalTrials.gov.
    • 05 Jun 2009 Actual initiation date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top